Organigram (TSE:OGI) Cut to Moderate Buy at ATB Cormark Capital Markets

ATB Cormark Capital Markets lowered shares of Organigram (TSE:OGI) from a strong-buy rating to a moderate buy rating in a report published on Wednesday, Marketbeat.com reports. ATB Cormark Capital Markets currently has C$3.25 price objective on the stock, down from their previous price objective of C$3.50.

Separately, Canaccord Genuity Group set a C$3.00 price objective on Organigram and gave the stock a “buy” rating in a research report on Tuesday, January 27th. Two investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of C$3.13.

Organigram Price Performance

TSE:OGI opened at C$1.74 on Wednesday. The company has a market cap of C$235.14 million, a price-to-earnings ratio of 11.30, a P/E/G ratio of 0.42 and a beta of 1.97. The company has a debt-to-equity ratio of 3.07, a quick ratio of 2.62 and a current ratio of 3.36. The stock’s fifty day moving average price is C$2.28 and its two-hundred day moving average price is C$2.29. Organigram has a 52-week low of C$1.22 and a 52-week high of C$3.09.

Organigram Company Profile

Organigram Inc is a Canadian licensed producer of cannabis products. Organigram focuses on producing exceptional, indoor-grown cannabis for patients and adult recreational consumers, as well as developing global business partnerships.